Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment

[1]  A. Bhalla,et al.  Utility of FDG-PET-CT scanning in assessing the extent of disease activity and response to treatment in sarcoidosis , 2014, Lung India : official organ of Indian Chest Society.

[2]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Kubota,et al.  Clinical value of whole-body PET/CT in patients with active rheumatic diseases , 2014, Arthritis Research & Therapy.

[4]  S. Mori,et al.  Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy , 2014, Clinical Rheumatology.

[5]  G. Herrero-Beaumont,et al.  Tocilizumab in refractory aortitis: study on 16 patients and literature review. , 2014, Clinical and experimental rheumatology.

[6]  S. Mohammad,et al.  Effective Control of Polymyalgia Rheumatica With Tocilizumab , 2013, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[7]  C. Salvarani,et al.  Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. , 2013, Seminars in arthritis and rheumatism.

[8]  T. Kano,et al.  Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis. , 2013, Joint, bone, spine : revue du rhumatisme.

[9]  Y. Tsushima,et al.  The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. , 2012, Rheumatology.

[10]  V. Ambrosini,et al.  FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  A. Saraux,et al.  Contribution of the Polymyalgia Rheumatica Activity Score to Glucocorticoid Dosage Adjustment in Everyday Practice , 2012, The Journal of Rheumatology.

[12]  T. Hanafusa,et al.  FDG-PET/CT of polymyalgia rheumatica , 2011, Modern rheumatology.

[13]  John O. Prior,et al.  Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  K. Hagihara,et al.  Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica , 2010, The Journal of Rheumatology.

[15]  X. Bosch,et al.  Treatment of polymyalgia rheumatica: a systematic review. , 2009, Archives of internal medicine.

[16]  Ren-Shyan Liu,et al.  F-18 FDG PET/CT of polymyalgia rheumatica. , 2009, Clinical nuclear medicine.

[17]  M. López-Hoyos,et al.  Circulating cytokines in active polymyalgia rheumatica , 2009, Annals of the rheumatic diseases.

[18]  J. Bojsen-Møller,et al.  Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue‐to‐blood background ratio using positron emission tomography in healthy humans , 2009, Clinical physiology and functional imaging.

[19]  C. Peterfy,et al.  An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[20]  A. Saraux,et al.  Epidemiology, imaging, and treatment of giant cell arteritis. , 2008, Joint, bone, spine : revue du rhumatisme.

[21]  Mahboob Rahman,et al.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.

[22]  Wolfgang A. Weber,et al.  Monitoring chemotherapy and radiotherapy of solid tumors , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  L. Mortelmans,et al.  Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. , 2005, Rheumatology.

[24]  B. Leeb,et al.  A disease activity score for polymyalgia rheumatica , 2004, Annals of the rheumatic diseases.

[25]  A. Maes,et al.  Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. , 2000, The American journal of medicine.

[26]  V. Devauchelle,et al.  Prevalence of synovitis in patients with polymyalgia rheumatica and/or giant cell arteritis. , 1997, Revue du rhumatisme.

[27]  G. Hunder,et al.  Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. , 1982, Annals of internal medicine.

[28]  Hiroyuki YamashitaKazuo.  Whole-body fluorodeoxyglucose positron emission tomography/ computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis , 2012 .

[29]  S. Hayat.  Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial , 2008 .

[30]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[31]  R. Caporali,et al.  Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. , 2004, Annals of internal medicine.